drugset / Trial / NCT05461352

Long-Term Study of TS-142 in Patients with Insomnia

NCT05461352

Phase 3 Completed 401 enrolled Taisho Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, open-label, multi-center long-term study in patients with insomnia.

Timeline

Start
2022-10-11
Primary completion
2024-03-07
Completion
2024-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject TS-142 Small molecule 5 mg Oral
Subject TS-142 Small molecule 10 mg Oral

Indications